Seer (NASDAQ:SEER) Stock Price Down 0.5% – Time to Sell?

Seer, Inc. (NASDAQ:SEER) was down 0.5% during mid-day trading on Monday . The stock traded as low as $1.79 and last traded at $1.81. Approximately 218,058 shares were traded during mid-day trading, an increase of 85% from the average daily volume of 117,801 shares. The stock had previously closed at $1.82.

Analysts Set New Price Targets

Several research analysts recently commented on SEER shares. Wall Street Zen raised shares of Seer to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Seer in a report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Seer Trading Down 0.5%

The company’s fifty day simple moving average is $1.87 and its 200 day simple moving average is $2.04. The stock has a market capitalization of $100.98 million, a P/E ratio of -1.33 and a beta of 1.63.

Seer (NASDAQ:SEER) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The company had revenue of $4.12 million for the quarter, compared to the consensus estimate of $4.00 million. Seer had a negative return on equity of 25.88% and a negative net margin of 484.51%. Equities research analysts predict that Seer, Inc. will post -1.42 earnings per share for the current year.

Insider Buying and Selling at Seer

In other news, CEO Omid Farokhzad sold 33,838 shares of Seer stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $1.97, for a total transaction of $66,660.86. Following the completion of the sale, the chief executive officer owned 1,238,230 shares in the company, valued at approximately $2,439,313.10. This trade represents a 2.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 11.28% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Bridgeway Capital Management LLC grew its stake in Seer by 15.5% in the 2nd quarter. Bridgeway Capital Management LLC now owns 837,443 shares of the company’s stock worth $1,792,000 after buying an additional 112,100 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Seer by 16.5% during the 2nd quarter. Geode Capital Management LLC now owns 509,727 shares of the company’s stock worth $1,091,000 after acquiring an additional 72,265 shares during the last quarter. Jane Street Group LLC grew its position in Seer by 33.3% in the first quarter. Jane Street Group LLC now owns 254,174 shares of the company’s stock worth $430,000 after acquiring an additional 63,432 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Seer by 51.6% in the first quarter. Goldman Sachs Group Inc. now owns 170,897 shares of the company’s stock valued at $289,000 after acquiring an additional 58,173 shares during the last quarter. Finally, Shay Capital LLC raised its position in Seer by 17.7% during the third quarter. Shay Capital LLC now owns 73,571 shares of the company’s stock valued at $160,000 after purchasing an additional 11,073 shares in the last quarter. 75.20% of the stock is currently owned by institutional investors.

Seer Company Profile

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.